ABEO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Abeona Therapeutics Inc (ABEO) does not present a strong buy opportunity for a beginner, long-term investor at this time. The technical indicators are bearish, options sentiment leans negative, and there are no recent positive news catalysts or significant insider/hedge fund activity to support a strong entry point. While the company has shown improvement in financial performance, the stock's current price trend and lack of strong trading signals suggest holding off on investment for now.
The technical indicators for ABEO are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 26.684, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with S1 at 4.334 and S2 at 4.16, indicating potential further downside.
Gross margin remains strong at 80.74%.
The stock has experienced consistent price declines (-2.04% in regular market hours and -0.46% post-market). Analysts have lowered the price target from $27.50 to $20, reflecting a more conservative outlook on the company's growth trajectory. There is no recent news or significant insider/hedge fund activity to support a bullish case.
In Q4 2025, revenue remained flat at $5.42M YoY. However, net income improved significantly to -$20.46M (up 120.17% YoY), and EPS increased to -0.37 (up 94.74% YoY). Gross margin remained strong at 80.74%.
Analysts maintain a Buy rating but have lowered the price target from $27.50 to $20, citing a more conservative launch trajectory for Zevaskyn. This reflects tempered expectations for growth in the near term.
